IN8bio to Present Data Highlighting Potential of INB-200 and INB-400 to Treat Patients with Newly Diagnosed Glioblastoma Multiforme at Society for Neuro-Oncology Annual Meeting
Portfolio Pulse from Benzinga Newsdesk
IN8bio, Inc. (NASDAQ:INAB) will present two posters at the Society for Neuro-Oncology (SNO) 28th Annual Meeting, highlighting the potential of its DeltEx Drug Resistant Immunotherapy (DRI) to treat patients with newly diagnosed glioblastoma multiforme (GBM). The posters will detail the study design for INB-400, the company-sponsored Phase 2 trial, and provide updated clinical data from the Phase 1 INB-200 trial.
November 10, 2023 | 12:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
IN8bio's presentation at the SNO Annual Meeting could potentially boost investor confidence if the data presented shows promising results for the INB-200 and INB-400 trials.
The presentation of positive data from IN8bio's INB-200 and INB-400 trials at a reputable conference could potentially increase investor confidence in the company's innovative therapies, leading to a potential increase in the company's stock price.
CONFIDENCE 75
IMPORTANCE 80
RELEVANCE 100